VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment

J. Qiao, J. Moreno, L. Sanchez-Perez, T. Kottke, J. Thompson, M. Caruso, R. M. Diaz, Richard G. Vile

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Low levels of gene delivery in vivo using replication-defective retroviral vectors have severely limited their application for clinical protocols. To overcome this problem, we describe here a semi-replication-competent retrovirus (s-RCR) in which the gag-pol and envelope (VSV-G, vesicular stomatitis virus G protein) genes were split into two vectors. This system offers potential advantages over both replication-defective vectors, in terms of efficiency of in vivo spread through a tumor, and all-in-one replication-competent vectors in terms of the payload of therapeutic genes that can be carried. We achieved a viral titer of s-RCR viruses approximately 70-fold higher than VSV-G pseudotyped, replication-defective vectors. In addition, s-RCR vectors induced tumor killing by the cytotoxicity of VSV-G during viral spread. Inclusion of the herpes simplex virus thymidine kinase (HSVtk30) gene into vectors significantly improved tumor killing activity followed by ganciclovir (GCV) treatment in vitro under conditions of low-level viral replication. However, at high levels of viral spread, VSV-G-mediated cytotoxicity predominated. Xenografts of human fibrosarcoma HT1080 cells, preinfected by semi-replicative green fluorescent protein vectors (semi-GFP), were completely non-tumorigenic in nude mice. Implantation of cells preinfected by semi-replicative TK30 vectors (semi-TK30) mixed with parental HT1080 cells at a ratio of 1:1 efficiently prevented tumor growth in mice treated by GCV. Direct intratumoral injection of HT1080 tumors growing in nude mice, or B16 murine melanoma in immunocompetent mice, with semi-TK30 viruses significantly prolonged survival. Injection of autologous cells (B16) producing semi-TK30 vector into B16 tumors prolonged survival only in mice treated with GCV but not with phosphate-buffered saline (PBS). In contrast, when xenogeneic cells (293T) producing semi-TK30 vectors were injected into B16 tumors, an optimal survival advantage was obtained in mice treated with PBS rather than GCV. These data indicate that complex interactions exist between direct cytotoxicity of VSV-G and HSVtk expression when placed in the context of additional immune parameters, which combine to determine the efficacy of the therapy. Taken together, our data suggest that s-RCR vectors have some potential advantages for development to deliver genes into tumors for cancer treatment but that a combination of factors will impact on the decision as to whether the s-RCR strategy is worth developing to full clinical trials.

Original languageEnglish (US)
Pages (from-to)1457-1470
Number of pages14
JournalGene Therapy
Volume13
Issue number20
DOIs
StatePublished - Oct 1 2006

Fingerprint

Retroviridae
Ganciclovir
Neoplasms
Therapeutics
Genes
Nude Mice
Survival
Phosphates
Viruses
vesicular stomatitis virus G protein
Experimental Melanomas
Injections
Thymidine Kinase
Fibrosarcoma
HEK293 Cells
Simplexvirus
Clinical Protocols
Green Fluorescent Proteins
Heterografts
Clinical Trials

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Qiao, J., Moreno, J., Sanchez-Perez, L., Kottke, T., Thompson, J., Caruso, M., ... Vile, R. G. (2006). VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. Gene Therapy, 13(20), 1457-1470. https://doi.org/10.1038/sj.gt.3302782

VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. / Qiao, J.; Moreno, J.; Sanchez-Perez, L.; Kottke, T.; Thompson, J.; Caruso, M.; Diaz, R. M.; Vile, Richard G.

In: Gene Therapy, Vol. 13, No. 20, 01.10.2006, p. 1457-1470.

Research output: Contribution to journalArticle

Qiao, J, Moreno, J, Sanchez-Perez, L, Kottke, T, Thompson, J, Caruso, M, Diaz, RM & Vile, RG 2006, 'VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment', Gene Therapy, vol. 13, no. 20, pp. 1457-1470. https://doi.org/10.1038/sj.gt.3302782
Qiao J, Moreno J, Sanchez-Perez L, Kottke T, Thompson J, Caruso M et al. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. Gene Therapy. 2006 Oct 1;13(20):1457-1470. https://doi.org/10.1038/sj.gt.3302782
Qiao, J. ; Moreno, J. ; Sanchez-Perez, L. ; Kottke, T. ; Thompson, J. ; Caruso, M. ; Diaz, R. M. ; Vile, Richard G. / VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. In: Gene Therapy. 2006 ; Vol. 13, No. 20. pp. 1457-1470.
@article{01cd89051dfb410fba70279a9a583eb3,
title = "VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment",
abstract = "Low levels of gene delivery in vivo using replication-defective retroviral vectors have severely limited their application for clinical protocols. To overcome this problem, we describe here a semi-replication-competent retrovirus (s-RCR) in which the gag-pol and envelope (VSV-G, vesicular stomatitis virus G protein) genes were split into two vectors. This system offers potential advantages over both replication-defective vectors, in terms of efficiency of in vivo spread through a tumor, and all-in-one replication-competent vectors in terms of the payload of therapeutic genes that can be carried. We achieved a viral titer of s-RCR viruses approximately 70-fold higher than VSV-G pseudotyped, replication-defective vectors. In addition, s-RCR vectors induced tumor killing by the cytotoxicity of VSV-G during viral spread. Inclusion of the herpes simplex virus thymidine kinase (HSVtk30) gene into vectors significantly improved tumor killing activity followed by ganciclovir (GCV) treatment in vitro under conditions of low-level viral replication. However, at high levels of viral spread, VSV-G-mediated cytotoxicity predominated. Xenografts of human fibrosarcoma HT1080 cells, preinfected by semi-replicative green fluorescent protein vectors (semi-GFP), were completely non-tumorigenic in nude mice. Implantation of cells preinfected by semi-replicative TK30 vectors (semi-TK30) mixed with parental HT1080 cells at a ratio of 1:1 efficiently prevented tumor growth in mice treated by GCV. Direct intratumoral injection of HT1080 tumors growing in nude mice, or B16 murine melanoma in immunocompetent mice, with semi-TK30 viruses significantly prolonged survival. Injection of autologous cells (B16) producing semi-TK30 vector into B16 tumors prolonged survival only in mice treated with GCV but not with phosphate-buffered saline (PBS). In contrast, when xenogeneic cells (293T) producing semi-TK30 vectors were injected into B16 tumors, an optimal survival advantage was obtained in mice treated with PBS rather than GCV. These data indicate that complex interactions exist between direct cytotoxicity of VSV-G and HSVtk expression when placed in the context of additional immune parameters, which combine to determine the efficacy of the therapy. Taken together, our data suggest that s-RCR vectors have some potential advantages for development to deliver genes into tumors for cancer treatment but that a combination of factors will impact on the decision as to whether the s-RCR strategy is worth developing to full clinical trials.",
author = "J. Qiao and J. Moreno and L. Sanchez-Perez and T. Kottke and J. Thompson and M. Caruso and Diaz, {R. M.} and Vile, {Richard G.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1038/sj.gt.3302782",
language = "English (US)",
volume = "13",
pages = "1457--1470",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "20",

}

TY - JOUR

T1 - VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment

AU - Qiao, J.

AU - Moreno, J.

AU - Sanchez-Perez, L.

AU - Kottke, T.

AU - Thompson, J.

AU - Caruso, M.

AU - Diaz, R. M.

AU - Vile, Richard G.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Low levels of gene delivery in vivo using replication-defective retroviral vectors have severely limited their application for clinical protocols. To overcome this problem, we describe here a semi-replication-competent retrovirus (s-RCR) in which the gag-pol and envelope (VSV-G, vesicular stomatitis virus G protein) genes were split into two vectors. This system offers potential advantages over both replication-defective vectors, in terms of efficiency of in vivo spread through a tumor, and all-in-one replication-competent vectors in terms of the payload of therapeutic genes that can be carried. We achieved a viral titer of s-RCR viruses approximately 70-fold higher than VSV-G pseudotyped, replication-defective vectors. In addition, s-RCR vectors induced tumor killing by the cytotoxicity of VSV-G during viral spread. Inclusion of the herpes simplex virus thymidine kinase (HSVtk30) gene into vectors significantly improved tumor killing activity followed by ganciclovir (GCV) treatment in vitro under conditions of low-level viral replication. However, at high levels of viral spread, VSV-G-mediated cytotoxicity predominated. Xenografts of human fibrosarcoma HT1080 cells, preinfected by semi-replicative green fluorescent protein vectors (semi-GFP), were completely non-tumorigenic in nude mice. Implantation of cells preinfected by semi-replicative TK30 vectors (semi-TK30) mixed with parental HT1080 cells at a ratio of 1:1 efficiently prevented tumor growth in mice treated by GCV. Direct intratumoral injection of HT1080 tumors growing in nude mice, or B16 murine melanoma in immunocompetent mice, with semi-TK30 viruses significantly prolonged survival. Injection of autologous cells (B16) producing semi-TK30 vector into B16 tumors prolonged survival only in mice treated with GCV but not with phosphate-buffered saline (PBS). In contrast, when xenogeneic cells (293T) producing semi-TK30 vectors were injected into B16 tumors, an optimal survival advantage was obtained in mice treated with PBS rather than GCV. These data indicate that complex interactions exist between direct cytotoxicity of VSV-G and HSVtk expression when placed in the context of additional immune parameters, which combine to determine the efficacy of the therapy. Taken together, our data suggest that s-RCR vectors have some potential advantages for development to deliver genes into tumors for cancer treatment but that a combination of factors will impact on the decision as to whether the s-RCR strategy is worth developing to full clinical trials.

AB - Low levels of gene delivery in vivo using replication-defective retroviral vectors have severely limited their application for clinical protocols. To overcome this problem, we describe here a semi-replication-competent retrovirus (s-RCR) in which the gag-pol and envelope (VSV-G, vesicular stomatitis virus G protein) genes were split into two vectors. This system offers potential advantages over both replication-defective vectors, in terms of efficiency of in vivo spread through a tumor, and all-in-one replication-competent vectors in terms of the payload of therapeutic genes that can be carried. We achieved a viral titer of s-RCR viruses approximately 70-fold higher than VSV-G pseudotyped, replication-defective vectors. In addition, s-RCR vectors induced tumor killing by the cytotoxicity of VSV-G during viral spread. Inclusion of the herpes simplex virus thymidine kinase (HSVtk30) gene into vectors significantly improved tumor killing activity followed by ganciclovir (GCV) treatment in vitro under conditions of low-level viral replication. However, at high levels of viral spread, VSV-G-mediated cytotoxicity predominated. Xenografts of human fibrosarcoma HT1080 cells, preinfected by semi-replicative green fluorescent protein vectors (semi-GFP), were completely non-tumorigenic in nude mice. Implantation of cells preinfected by semi-replicative TK30 vectors (semi-TK30) mixed with parental HT1080 cells at a ratio of 1:1 efficiently prevented tumor growth in mice treated by GCV. Direct intratumoral injection of HT1080 tumors growing in nude mice, or B16 murine melanoma in immunocompetent mice, with semi-TK30 viruses significantly prolonged survival. Injection of autologous cells (B16) producing semi-TK30 vector into B16 tumors prolonged survival only in mice treated with GCV but not with phosphate-buffered saline (PBS). In contrast, when xenogeneic cells (293T) producing semi-TK30 vectors were injected into B16 tumors, an optimal survival advantage was obtained in mice treated with PBS rather than GCV. These data indicate that complex interactions exist between direct cytotoxicity of VSV-G and HSVtk expression when placed in the context of additional immune parameters, which combine to determine the efficacy of the therapy. Taken together, our data suggest that s-RCR vectors have some potential advantages for development to deliver genes into tumors for cancer treatment but that a combination of factors will impact on the decision as to whether the s-RCR strategy is worth developing to full clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=33749248007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749248007&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302782

DO - 10.1038/sj.gt.3302782

M3 - Article

VL - 13

SP - 1457

EP - 1470

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 20

ER -